Tercica announces court rulings in United Kingdom regarding patent litigation against Insmed and Avecia.Tercica, Inc. (South San Francisco South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , CA) announced that the High Court of Justice (Chancery Division Patent Court) in London issued rulings in the patent infringement patent infringement n. the manufacture and/or use of an invention or improvement for which someone else owns a patent issued by the government, without obtaining permission of the owner of the patent by contract, license or waiver. litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. case of Tercica, Inc. vs. Insmed Inc. and Avecia Limited, and in the related patent revocation action of Insmed Inc. and Avecia Limited vs Genentech, Inc. Insmed and Avecia had made motions for summary judgment in each matter. Their motions attacked the validity of the Tercica/Genentech patent at issue. The Court ruled in Tercica's and Genentech's favor in denying both motions. The Court also ordered Insmed and Avecia to pay Tercica's and Genentech's legal fees. "The Court heard extensive oral arguments on the issue of validity of the patent for several days and denied Insmed and Avecia's motions. Based on these favorable rulings, we are now in a position to expeditiously ex·pe·di·tious adj. Acting or done with speed and efficiency. See Synonyms at fast1. ex pursue all our legal remedies to prevent Avecia, Insmed's contract manufacturer, from infringing on our patent and making products in the United Kingdom for Insmed to market and sell in the United States and elsewhere," said Stephen N. Rosenfield, Tercica's Senior Vice President of Legal Affairs and General Counsel. Tercica's suit in the UK alleges that by making, using, and selling the SomatoKine product in the United Kingdom for the treatment of Growth Hormone Insensitivity Syndrome growth hormone insensitivity syndrome Laron dwarfism, pituitary dwarfism II An AR condition characterized by severe growth retardation, delayed bone age, occasionally blue sclerae, and physical manifestations of GH deficiency, due to a defect in the GH receptor (GHIS GHIS Growth Hormone Insensitivity Syndrome GHIS Geosynchronous High-Resolution Interferometer Sounder ), Avecia and Insmed infringe a European (UK) patent under which Tercica holds an exclusive license from Genentech. SomatoKine is a complex of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor insulin-like growth factor one of the twenty or so substances, additional to the classic bone-regulating hormones, which exert an effect on bone cell metabolism. See also somatomedin C. binding protein-3 (IGFBP-3). Tercica licensed world-wide rights to develop, manufacture and commercialize rhIGF-1 and IGF-1/IGFBP-3 from Genentech. Tercica is a biopharmaceutical company focused on the development and commercialization of products to improve endocrine health. The company's first product candidate, Increlex (mecasermin (rDNA origin) injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is being developed for the treatment of short stature and associated metabolic disorders. Tercica, Inc. +1-650-624-4949 www.tercica.com |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion